LIFE News and Press, aTyr Pharma Inc. From 05/25/23

SAN DIEGO, May 25, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Execut...

Advancement in mechanistic understanding of efzofitimod’s modulation of myeloid cells to be featured in symposia presentation. Exposure-efficacy data from Phase 1b/2a study of efzofitimod support efficacy across multiple clinically relevant endpoints in pulmonary sarcoidosis pati...

SAN DIEGO, May 11, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that Sanjay S. Shukla, M.D., M.S., President and Chief Execut...

2023-05-09 17:30:06 ET aTyr Pharma press release ( NASDAQ: LIFE ): Q1 GAAP EPS of -$0.29. Ended the first quarter 2023 with $117.6 million in cash, cash equivalents and investments. For further details see: aTyr Pharma GAAP EPS of -$0.29

Phase 3 EFZO-FIT™ study of efzofitimod in patients with pulmonary sarcoidosis currently enrolling in the U.S., Europe and Japan. Phase 2 proof-of-concept study of efzofitimod in patients with SSc-ILD expected to initiate in the third quarter of 2023. Company to host multi...

2023-05-07 04:00:41 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips If you are only concerned about upside potential, looking into some stocks and cryptos with high returns is the way to go. The current environment is indeed very risky, with a recent rate hik...

SAN DIEGO, April 17, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced a poster presentation at the 2023 American Association fo...

SAN DIEGO, March 30, 2023 (GLOBE NEWSWIRE) --  aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced the publication of a review article, titled, “...

2023-03-29 08:22:10 ET Arcturus Therapeutics Holdings  ( ARCT ) +28% Q4 earnings call release Lululemon Athletica  ( LULU ) +17% Q4 earnings call release Jiayin Group ( JFIN ) +15% Q4 earnings call release N-able ( NABL ) +13% jumps ...

Findings confirm LTBP1, a key regulator of TGF-β, as binding partner for tRNA synthetase DARS fragment ATYR0101 Data indicates ATYR0101 may have therapeutic potential for fibrotic pathologies SAN DIEGO, March 21, 2023 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a bi...